Quick answer: in Foundayo vs Wegovy pill, both are once-daily GLP-1 pills FDA-approved for weight loss in adults, but they differ in drug, routine and results.[7][8] The Wegovy pill (oral semaglutide 25 mg) produced 13.6% average weight loss at 64 weeks, but must be taken on an empty stomach.[2] Foundayo (orforglipron) produced 11.1% at its top dose over 72 weeks and can be taken with or without food.[1] They have never been tested head to head for weight loss.
For each drug on its own, see the Wegovy pill guide and the Foundayo dosage guide. For all oral options, including Rybelsus, see GLP-1 pills.
Foundayo vs Wegovy pill at a glance
| Foundayo | Wegovy pill | |
|---|---|---|
| Active drug | Orforglipron, a small non-peptide molecule | Semaglutide, a peptide, with absorption enhancer SNAC |
| Maker | Eli Lilly | Novo Nordisk |
| FDA approval | April 1, 2026 | December 22, 2025 |
| Approved uses | Weight reduction and maintenance in adults | Weight reduction and maintenance; lower heart risk in adults with heart disease |
| Dose steps | 0.8 → 2.5 → 5.5 mg, optional 9, 14.5, 17.2 mg | 1.5 → 4 → 9 → 25 mg |
| Time to usual dose | At least 60 days to 5.5 mg | 90 days to 25 mg |
| Food and drink | With or without food | Empty stomach, ≤4 oz water, wait 30 minutes |
| Missed dose | Take when remembered; restart lower after 7+ missed | Skip it; take the next one the following day |
Sources: FDA labels[1][2] and Drugs@FDA.[7][8]
How they work
Both activate the GLP-1 receptor, which lowers appetite and slows stomach emptying. The difference is chemistry. Semaglutide is a peptide that stomach acid normally destroys, so each Wegovy tablet carries SNAC to help absorption, and only about 1% to 2% of the dose reaches the blood.[2] Orforglipron is a small molecule built to survive digestion; about 77% of a dose is absorbed.[3][1]
That explains the routine gap. For the Wegovy pill, food, other drinks or too much water can reduce absorption, which is why the label limits it to 4 ounces of plain water. Food changes Foundayo levels only slightly.[2][1]
Weight loss: what each trial found
| Foundayo (ATTAIN-1) | Wegovy pill (OASIS 4) | |
|---|---|---|
| People | 3,127 adults without diabetes | 307 adults without diabetes |
| Length | 72 weeks | 64 weeks |
| Average weight change, top dose | −11.1% (17.2 mg) | −13.6% (25 mg) |
| Placebo | −2.1% | −2.4% |
| Lost at least 15% | 35.9% | 47.0% |
| Lost at least 20% | 18.4% | 27.9% |
The Wegovy pill’s numbers are higher, but the trials differ in size, length, the people enrolled and how missing data were handled, so the gap is an estimate, not a verdict.[3][4] OASIS 4 was much smaller, and most of its participants were White women.[2]
With type 2 diabetes: Foundayo’s ATTAIN-2 trial found 9.6% weight loss on the top dose versus 2.5% on placebo over 72 weeks.[6] The Wegovy pill has not been studied for weight loss in people with type 2 diabetes. Its label notes lower semaglutide levels from the tablet in this group and suggests considering the injection if the response is poor.[2]
Side effects compared
Both cause the typical GLP-1 stomach side effects, worst while the dose is rising.
| Foundayo (pooled trials) | Wegovy pill (OASIS 4) | |
|---|---|---|
| Any stomach side effect | 60% to 69% by dose (placebo 37%) | 74.0% (placebo 42.2%) |
| Stopped due to side effects | 8% (placebo 3%) | 6.9% (placebo 5.9%) |
| Altered skin sensation | 0% to 1% by dose | 5% (placebo 0%) |
| Heart rate | Up 4 to 5 beats per minute (placebo 0.5) | Up 2.7 beats per minute (placebo 2.4) |
Sources: FDA labels[1][2] and the OASIS 4 paper.[4]
Both labels carry the same boxed warning about thyroid C-cell tumors seen in rodents, and both say not to use the drug with a personal or family history of medullary thyroid cancer or MEN 2.[1][2] Both list pancreatitis, gallbladder disease, kidney injury from dehydration and aspiration during anesthesia as warnings. Neither is recommended while breastfeeding.
Interactions and other medicines
- Foundayo is broken down by the liver enzyme CYP3A4. Strong inhibitors such as clarithromycin cap the dose at 9 mg, and strong inducers such as carbamazepine should be avoided. It also raises the active form of simvastatin about twofold.[1]
- Birth control pills: Foundayo’s label advises a non-oral or backup method for 30 days after starting and after each dose increase.[1]
- Wegovy pill: the 30-minute wait applies to all other oral medicines, which can be awkward for people who take several pills in the morning.[2]
Switching from an injection
Many people considering a pill are already on a weekly injection. The two labels handle this differently.
- Wegovy injection to the Wegovy pill: the label gives a direct path. People on the 2.4 mg weekly injection can start 25 mg tablets one week after their last shot, and can go back to the 2.4 mg injection the day after their last tablet.[2]
- Injection to Foundayo: the Foundayo label has no switching table, so the prescriber plans the start. In the ATTAIN-MAINTAIN trial, adults who had reached a plateau on tirzepatide or semaglutide injections were switched to orforglipron or placebo for a year. On orforglipron they kept an estimated 74.7% (after tirzepatide) and 79.3% (after semaglutide) of the weight they had lost, versus 49.2% and 37.6% on placebo.[9] There was no group that stayed on the injection.
Who should not take either pill
The two labels share most of their cautions:[1][2]
- Thyroid history: not for anyone with a personal or family history of medullary thyroid cancer or with MEN 2.
- Pregnancy: both may harm a fetus and should be stopped when pregnancy is recognized. The Wegovy label advises stopping at least 2 months before a planned pregnancy because semaglutide lasts a long time in the body.
- Severe gastroparesis: neither is recommended.
- Other GLP-1 drugs: neither should be combined with another GLP-1 medicine.
- Children: both pills are approved for adults only.
Both are stored at room temperature. The Wegovy tablets must stay in their original bottle to protect them from moisture, which rules out a weekly pill organizer.[2]
Which one may fit you?
Foundayo may suit people who:
- Want no fasting rules or have a busy morning routine.
- Have type 2 diabetes and want a pill tested for weight loss in that group.
- Do not take interacting medicines such as strong CYP3A4 inhibitors or inducers.
The Wegovy pill may suit people who:
- Want the larger average weight loss seen in its trial and can keep a strict morning routine.
- Have established heart disease, since the tablets are approved to lower heart risk.
- Might move between the pill and the weekly injection, which the label explains how to do.
Cost and coverage often decide it. See Foundayo cost and Wegovy pill cost. If you are also weighing injections, see orforglipron vs tirzepatide, oral vs injectable semaglutide and the GLP-1 drugs hub.
Questions to ask your clinician
- Given my health history, which pill has better evidence for me?
- Do my current medicines interact with either one?
- Can I realistically keep the Wegovy pill’s empty-stomach routine?
- What does my plan cover, and is prior authorization needed?
Talk with a licensed clinician before choosing or switching a weight-loss medicine.
